QM · rank #5 · 2026-09-07
LQDA
NASDAQ · $6.14B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +341.17% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +131.8% |
| Profit margin Net profit margin, trailing 12 months. | +30.7% |
| Market cap (USD) Size filter: > $500M required. | $6.14B |
| Anchor (recent) Close on 2026-08-07 | $90.22 |
| Anchor (far) Close on 2025-08-08 | $20.45 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies is a focused rare cardiopulmonary drug company commercializing YUTREPIA, a dry-powder inhaled treprostinil for PAH and PH-ILD, with no other meaningful revenue streams.
Rationale
The quality_momentum signal is well-supported: YUTREPIA net sales grew 31% sequentially to $170.4M in Q2 2026, the fourth consecutive profitable quarter, and a 1.32 ROE with 30%+ profit margins confirm the business has crossed into durable, high-quality earnings generation rather than mere sentiment-driven momentum.
Material risks
- 1Single-product concentration in YUTREPIA means any safety signal, generic treprostinil inhalation entrant, or adverse label change would collapse the entire revenue base with no offset — this is the most concrete thesis-breaker given the moat rests on formulation/device differentiation, not long-duration IP exclusivity or contracted backlog.
- 2Payer pressure and reimbursement risk on a high-cost specialty therapy could compress the strong margins that underpin the quality signal, particularly as YUTREPIA scales and draws greater scrutiny from PBMs and specialty pharmacy benefit managers.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.